Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Phase II trial of maintenance therapy with iberdomide after autologous hematopoietic cell transplant for patients with multiple myeloma previously treated with lenalidomide

Blood (2025) 146 (Supplement 1): 4048.

https://doi.org/10.1182/blood-2025-4048

Published: 2025

Journal Articles

Plasma cell leukemia: A single institution review of cases

Richa Thakur, Phyu Thin Naing, Anthony Corsi, Kelvin Zheng, Divya Chukkalore, Salman Khan, David Chung, Jessica Caro

Blood (2025) 146 (Supplement 1): 8123.

https://doi.org/10.1182/blood-2025-8123

Published: 2025

Journal Articles

Infection rates and mortality in multiple myeloma: Impact of blood counts and IgG levels over time

Neha Puttagunta, Phyu Thin Naing, Alex Luc, Anthony Corsi, Kelvin Zheng, Divya Chukkalore, Richa Thakur, Salman Khan, David Chung, Jessica Caro

Blood (2025) 146 (Supplement 1): 7512.

https://doi.org/10.1182/blood-2025-7512

Published: 2025

Journal Articles

Real-world analysis of infection timing and burden in multiple myeloma patients treated with teclistamab

Divya Chukkalore, Phyu Thin Naing, Anthony Corsi, Kelvin Zheng, Richa Thakur, Salman Khan, David Chung, Jessica Caro

Blood (2025) 146 (Supplement 1): 7511.

https://doi.org/10.1182/blood-2025-7511

Published: 2025

Journal Articles

Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial

Blood (2025) 146 (Supplement 1): 2273.

https://doi.org/10.1182/blood-2025-2273

Published: 2025

Journal Articles

Factors associated with remote healthcare utilization in MM patients undergoing autologous stem cell transplantation

Blood (2025) 146 (Supplement 1): 2632.

https://doi.org/10.1182/blood-2025-2632

Published: 2025

Journal Articles

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2023-187891

Published: 2023

Journal Articles

T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis

Nezar Mehanna, Andriy Derkach, Billel Gasmi, Theodora Anagnostou, Heather Landau, Oscar Boutros Lahoud, Michael Scordo, Gunjan L. Shah, Hani Hassoun, Kylee H Maclachlan, Malin Hultcrantz, Neha Korde, Sham Mailankody, Urvi A Shah, Carlyn Rose Tan, Saad Z Usmani, Sergio A. Giralt, Alexander Lesokhin, David Chung

Blood (2023) 142 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2023-177960

Published: 2023

Journal Articles

Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma

Blood (2023) 142 (Supplement 1): 877.

https://doi.org/10.1182/blood-2023-180315

Published: 2023

Journal Articles

The Complex Structural Variant Chromothripsis Can be Defined on Targeted Sequencing Panels, Allowing Direct Clinical Translation in Order to Improve Multiple Myeloma Prognostication

Blood (2023) 142 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2023-189316

Published: 2023

Journal Articles

Artificial Intelligence Enabled ECG Interpretation Informs Outcomes after Autologous Transplantation for Multiple Myeloma

Brian C. Shaffer, Itzhak Zachi Attia, Grace Greason, Stephanie Chinapen, Samantha Brown, David Chung, Oscar Boutros Lahoud, Francisco Lopez-Jimenez, Wendy Schaffer, Jennifer Liu, Sergio A. Giralt, Gunjan L. Shah, Heather Landau, Saad Z Usmani, Paul A Friedman, Bernard J Gersh, Peter Noseworthy, Ioanna Kosmidou

Blood (2023) 142 (Supplement 1): 4965.

https://doi.org/10.1182/blood-2023-184725

Published: 2023

Journal Articles

A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2023-179413

Published: 2023

Journal Articles

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 4744.

https://doi.org/10.1182/blood-2023-181868

Published: 2023

Journal Articles

A Whole Foods Plant-Based Weight Loss Intervention Improves Quality of Life, Metabolic, Microbiome and Immune Profile in MGUS/SMM As Well As Progression Trajectory in a Subset - the Nutrivention Trial

Blood (2023) 142 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2023-182878

Published: 2023

Journal Articles

Low Target Antigen Expression Mediates Resistance to BCMA CAR T Cell Therapy

Karlo Perica, Sarah Nataraj, Maria Lemdal Sjojstrand, Katherine Nagel, Emma Pavkovic, Erica Payson, Ana Cuenca, Anjali Patel, David Chung, Sham Mailankody, Gunjan L. Shah, Saad Z Usmani, Sergio A. Giralt, Michel Sadelain

Blood (2023) 142 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2023-178954

Published: 2023

Journal Articles

Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens

Blood (2023) 142 (Supplement 1): 2024.

https://doi.org/10.1182/blood-2023-190728

Published: 2023

Journal Articles

Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Blood (2023) 142 (Supplement 1): 1961.

https://doi.org/10.1182/blood-2023-180283

Published: 2023

Journal Articles

Stem Cell Utilization in the Era of Novel Therapies for Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2219.

https://doi.org/10.1182/blood-2023-188103

Published: 2023

Journal Articles

Identifying Causes of Unscheduled Healthcare Interactions and Changes to Patient Disposition in Individuals Receiving Outpatient Commercial Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 3707.

https://doi.org/10.1182/blood-2023-187889

Published: 2023

Journal Articles

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Blood (2023) 142 (Supplement 1): 333.

https://doi.org/10.1182/blood-2023-187467

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase II trial of maintenance therapy with iberdomide after autologous hematopoietic cell transplant for patients with multiple myeloma previously treated with lenalidomide

Plasma cell leukemia: A single institution review of cases

Infection rates and mortality in multiple myeloma: Impact of blood counts and IgG levels over time

Real-world analysis of infection timing and burden in multiple myeloma patients treated with teclistamab

Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial

Factors associated with remote healthcare utilization in MM patients undergoing autologous stem cell transplantation

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis

Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma

The Complex Structural Variant Chromothripsis Can be Defined on Targeted Sequencing Panels, Allowing Direct Clinical Translation in Order to Improve Multiple Myeloma Prognostication

Artificial Intelligence Enabled ECG Interpretation Informs Outcomes after Autologous Transplantation for Multiple Myeloma

A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma

A Whole Foods Plant-Based Weight Loss Intervention Improves Quality of Life, Metabolic, Microbiome and Immune Profile in MGUS/SMM As Well As Progression Trajectory in a Subset - the Nutrivention Trial

Low Target Antigen Expression Mediates Resistance to BCMA CAR T Cell Therapy

Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens

Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Stem Cell Utilization in the Era of Novel Therapies for Multiple Myeloma

Identifying Causes of Unscheduled Healthcare Interactions and Changes to Patient Disposition in Individuals Receiving Outpatient Commercial Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only